LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Home・Aandelen Lijst・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

61.43 -4.73

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

60.08

Max

64.28

Belangrijke statistieken
By Trading Economics
Inkomsten	155M -24M
Verkoop	229M 256M
Winstmarge	-9.26
Werknemers	711
EBITDA	-546M -148M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	-5.88% downside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.7B 7.8B
Vorige openingsprijs	66.16
Vorige sluitingsprijs	61.43

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

11.5 / 12.23 Steun & Weerstand

Arrowhead Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 dec 2025, 21:08 UTC

Acquisities, Fusies, Overnames

Meta Platforms Buys AI-Device Maker Limitless

5 dec 2025, 19:39 UTC

Belangrijke Marktbewegers

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dec 2025, 19:17 UTC

Acquisities, Fusies, Overnames

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

5 dec 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dec 2025, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

5 dec 2025, 21:50 UTC

Acquisities, Fusies, Overnames

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dec 2025, 21:36 UTC

Marktinformatie

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dec 2025, 21:35 UTC

Acquisities, Fusies, Overnames

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dec 2025, 21:12 UTC

Marktinformatie

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dec 2025, 21:03 UTC

Marktinformatie

Winsten

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dec 2025, 21:01 UTC

Marktinformatie

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dec 2025, 20:43 UTC

Acquisities, Fusies, Overnames

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dec 2025, 20:42 UTC

Acquisities, Fusies, Overnames

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dec 2025, 20:01 UTC

Acquisities, Fusies, Overnames

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dec 2025, 19:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 dec 2025, 19:44 UTC

Marktinformatie

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dec 2025, 19:39 UTC

Marktinformatie

Silver Climbs to a New Record High -- Market Talk

5 dec 2025, 19:31 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:30 UTC

Marktinformatie

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dec 2025, 18:28 UTC

Acquisities, Fusies, Overnames

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dec 2025, 18:24 UTC

Acquisities, Fusies, Overnames

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

5 dec 2025, 18:20 UTC

Marktinformatie

Baker Hughes Reports Higher U.S. Rig Count -- Market Talk

5 dec 2025, 18:11 UTC

Marktinformatie

The Tale of Two Canadian Employment Indicators -- Market Talk

5 dec 2025, 17:48 UTC

Marktinformatie

Canadian Youth Unemployment Rate Cools -- Market Talk

5 dec 2025, 17:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

5 dec 2025, 17:44 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Correction to Imax Market Talk

5 dec 2025, 17:35 UTC

Marktinformatie

Canada Jobs Data Doesn't Jive With Trade Uncertainty, Indicators -- Market Talk

5 dec 2025, 17:25 UTC

Marktinformatie

Canadian Jobs Numbers May Support Rates Hikes Next Year -- Market Talk

Peer Vergelijking

Prijswijziging

Arrowhead Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

-5.88% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 60.86 USD -5.88%

Hoogste 85 USD

Laagste 48 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arrowhead Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Arrowhead Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

11.5 / 12.23Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.